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RAWATAN HIV/AIDS DAN KUALITI KEHIDUPAN YANG BERKAITAN 
DENGAN KESIHATAN: PERSPEKTIF PESAKIT DAN KESAN SAMPINGAN 
UBAT DALAM KALANGAN PESAKIT HIV/AIDS 
ABSTRAK 
Kemajuan rawatan antiretroviral (ART) dan perubahan HIV sebagai jangkitan yang 
kronik, memberi cabaran seperti kesan sampingan ubat (ADRs) yang yang 
mempengaruhi pematuhan dan pengekalan rawatan dan juga kualiti kehidupan yang 
berkaitan kesihatan (HRQoL).  Oleh yang demikian, penilaian ADRs dan langkah-
langkah HRQoL adalah amat penting dalam memaksimumkan keseluruhan hasil 
rawatan. Penglibatan pesakit secora mendalam tentang rawatan mereka boleh 
membantu meningkatkan dapatan rawatan serta pemahaman dan kepercayaan pesakit 
terhadap penyakit, rawatan dan isu-isu berkaitan adalah penting dalam keseluruhan 
penjagaan HIV. 
Kajian ini telah dijalankan di Hospital Sungai Buloh. Seramai empat ratus dan empat 
puluh tiga pesakit HIV/AIDS warganegara Malaysia yang menggunakan rawatan 
antiretroviral (ART) selama tiga bulan mengambil bahagian dalam kajian ini. Data telah 
dianalisa menggunakan Statistical Package for Social Sciences (SPSS®) versi 18 and 
STATA IC® versi 12. Kaedah kualitatif telah digunapakai untuk mendapatkan 
perspektif pesakit berkenaan penyakit, rawatan dan penjagaan. Temuduga separa 
struktur telah digunakan untuk menemuduga pesakit dan titik tepu telah dicapai setelah 
temuduga yang ke 13 dijalankan. Kesemua temuduga telah dirakam dan melalui 
rangkakerja analisa kandungan piawai.  
 xxi   
 
Sebanyak 44% (n=194) daripada keseluruhan 443 pesakit-pesakit HIV melaporkan 
ADR, termasuk penurunan berat badan (12.6%), ‘lipodystropi’ (12.4%) dan ‘neuropeti 
periferal’ (12%), Tahap CD4 yang menurun (OR 1.72, 95% CI: 1.04-2.86), dan 
kurangnya perencatan virus (OR 1.87, 95% CI: 1.04 — 3.36) telah meningkatkan 
kemungkinan terjadinya ADRs. Akibatnya pesakit-pesakit yang mengalami ADRs 
mengalami sebanyak 2.28 (95% CI: 1.25 – 4.18) risiko yang lebih tinggi dalam ketidak-
berkesanan pengawalan CD4. Status pendidikan dan pekerjaan peserta-peserta kajian 
tidak mendapat pendidikan formal telah mempengaruhi skor rendah yang signifikan 
bagi ‘physical composite scores’ (PCS) jika dibandingkan dengan peserta-peserta yang 
mempunyai pendidikan sekolah menengah (p=0.049) dan yang mem punyai kelulusan 
ijazah (p=0.003). Pesakit-pesakit yang tidak bekerja juga mempunyai skor yang rendah 
dalam domain PCS jika dibandingkan dengan pekerja buruh (p=0.003) dan profesional 
(p=0.006). ADRs juga didapati berkait-rapat dengan HRQoL yang rendah dalam 
pelbagai domain dan keseluruhan fizikal (p=0.001) dan mental (p=0.013) dalam kualiti 
kehidupan 
Beberapa tema penting telah diperolehi yang menunjukkan perspektif berbeza pesakit-
pesakit dalam rawatan HIV/AIDS. Walaupun kebanyakannya memahami HIV/AIDS 
dan puncanya, terdapat elemen-elemen kerohanian dan juga kurang pengetahuan. 
Walaupun kesedaran tentang status HIV wujud dalam kalangan pesakit, mereka lebih 
takut kepada stigma dan diskriminasi. Kesan-kesan sosial dan emosi keluarga telah 
didapati sebagai elemen-elemen penting yang mengaitkan penyakit dan keengganan 
untuk melalui proses pemeriksaan. Umumnya peserta-peserta percaya hanya ARTs 
sahaja rawatan yang sedia ada; kerisauan pada kesan sampingan, kurang sistem 
sokongan, putus asa, nilai-nilai negatif dan penggunaan rawatan pelengkap 
 xxii   
 
‘complementary’ dan alternatif juga didapati berkaitan dengan rawatan yang dipilih. 
Hierarki dalam kalangan doktor, masa menunggu untuk mendapatkan temujanji, hormat 
dan kerahsiaan didapati sebagai elemen-elemen penting yang memberi kesan kepada 
penerimaan pesakit-pesakit. 
Kurang maklumat dan keadaan yang tidak dapat diramalkan berkenaan ADRs terus 
memberi cabaran kepada pesakit-pesakit HIV/AIDS yang memerlukan fokus dalam 
penelitian perubatan bagi rawatan HIV. Gambaran kehidupan sebenar berkenaan 
perspektif pesakit-pesakit terhadap penyakit, rawatan dan penjagaan adalah penting 
dalam mereka-bentuk dan memperbaiki strategi sedia ada untuk meningkatkan kaedah 
penjagaan HIV yang perlu diberi lebih perhatian. Strategi seumpama ini adalah penting 
untuk berdepan dengan usaha negara didalam memenuhi objektif-objektif global di 
dalam penjagaan HIV 
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HIV/AIDS TREATMENT AND HEALTH-RELATED QUALITY OF LIFE: 
PATIENTS’ PERSPECTIVE AND IMPACT OF ADVERSE DRUG REACTIONS 
AMONG HIV/AIDS PATIENTS 
ABSTRACT 
 
Advancements in antiretroviral treatment (ART) and shift of HIV as a chronic infection, 
presents challenges, including adverse drug reactions (ADRs) affecting adherence and 
retention to care as well as health related quality of life (HRQoL); thus evaluation of 
ADRs and measures of HRQoL is imperative to maximize the overall treatment 
outcomes. In addition, greater involvement of the patients in their medical care can 
benefit treatment outcomes, thus understanding patients’ knowledge and beliefs towards 
disease, treatment and related issues are essential elements in overall HIV care. 
The present study was carried out at Hospital Sungai Buloh. Four hundred and forty three 
Malaysian HIV/AIDS patients, using Antiretroviral Therapy (ART) for at least three 
months, participated in this study. The data were analyzed using the Statistical Package 
for Social Sciences (SPSS®) version 18 and STATA IC® version 12. Qualitative 
methodology was used to explore patients’ perspectives on the disease, treatment and care 
with the help of a semi structured interview guide. A saturation point was reached after 
the 13th interview. All interviews were audio-recorded and subjected to a standard content 
analysis framework. 
About 44% (n=194) of the total 443 HIV patients reported ADR, among them weight loss 
(12.6%), lipodystrophy (12.4%), peripheral neuropathy (12%), were frequently found 
ADRs. Poor CD4 counts (OR 1.72, 95% CI: 1.04 — 2.86), and poor viral suppression 
(OR 1.87, 95% CI: 1.04 — 3.36) did increase the odds of experiencing ADRs, 
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consequently patients experiencing ADRs had a 2.28 (95% CI: 1.25 – 4.18) fold greater 
risk of poor CD4 control. As for QoL, participants with no formal education had 
significantly lower scores for physical composite scores (PCS) in comparison to those 
with secondary education (p=0.049) and graduates (p=0.003). Similarly unemployed 
patients had significantly lower scores under the PCS domain against laborers (p=0.003) 
and professionals (p=0.006). ADRs were also found significantly associated with lower 
HRQoL in various domains and overall physical (p=0.001) and mental (p=0.013) quality 
of life.  A number of important themes and subthemes emerged showing patients’ 
perspectives on HIV/AIDS treatment. Generally, participants had acceptable 
understandings towards the cause of disease; however elements of spirituality were also 
noted. Though strong beliefs existed towards the benefits of knowing HIV status, fear of 
stigma and discrimination, social consequences and family emotions were found 
important elements linked to status non-disclosure and refusal to get screened. Most 
participants believed in ARTs as the only available treatment; fear of side effects, lack of 
support system, gross hopelessness, and negative values were found reasons for non-
adherence. In addition, strong believes and use of complementary and alternative 
medicines were found linked to disease treatment. Doctors’ hierarchy, appointment 
waiting time, respect and confidentiality were seen as vital elements affecting patients’ 
satisfaction. Uninformed and unpredictable ADRs continue to challenge HIV/AIDS 
patients, requiring focus on pharmacovigilance in HIV care. A real life insight about 
patients’ perspectives towards disease, treatment and care is inevitable in designing and 
improvising existing strategies to enhance areas in HIV care that requires more attention. 
Such strategies are important to withstand with the country’s efforts in meeting global 
objectives of HIV care. 
 1 
CHAPTER 1 
INTRODUCTION 
 
1.1 Introduction and background to HIV & AIDS 
 
1.1.1 Historical Background 
Human immunodeficiency virus (HIV) have been spreading through the human 
population long before AIDS was first described in 1981 [1], when increasing numbers 
of young homosexual men succumbed to unusual opportunistic infections and rare 
malignancies [2]. A retrovirus, now termed human immunodeficiency virus type 1 
(HIV-1), was identified as the causative agent of what has since become one of the most 
devastating infectious diseases to have emerged in recent history [3]. It was in 1986 
when a morphologically similar but antigenically distinct virus was found to cause 
AIDS in patients in western Africa and this new virus was then termed as human 
immunodeficiency virus type 2 (HIV-2) [4]. Both of these viruses belong to lentiviruses 
family and it is also interesting to know that they are believed to be a result of multiple 
cross-species transmissions of simian immunodeficiency viruses (SIVs) naturally 
infecting African primates resulting in gradual immune deficiencies in human being [4].  
Chronic immune activation is a hallmark of HIV disease and results in increased viral 
replication and immune cell depletion, immune cell dysfunction, and aberrant 
lymphocyte turnover [5], therefore once infected the disease process could result in a 
clinical latent period of a few years before clinical, constitutional symptoms of disease 
can be seen [5,6]. This period has a great importance in strategizing behavioral and 
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pathogenesis based interventions in limiting HIV epidemics as individuals with acute 
HIV infection (AHI) pose a greater transmission risk than most chronically infected 
patients, hence prevention efforts targeting these individuals are important for reducing 
the spread of HIV infection [6–8]. 
 
As for disease epidemic sexual transmission, injecting drug use (IDU) and vertical 
transmission from mother to child are regarded as the major ways of HIV transmission 
[4,6]. Sexual transmission is still accounted as a major route of HIV/AIDS globally [6], 
therefore the Joint United Nations Programme on HIV/AIDS (UNAIDS) has targeted a 
50% reduction in sexual transmission among low-and middle income developing 
countries by year 2015 [9].  
 
 
1.1.2 HIV/AIDS treatment 
The unprecedented efforts in the fields of biology, pharmacology and clinical care have 
contributed to progressively turn HIV infection from an inevitably fatal condition into a 
chronic manageable disease [10]. Recent advances in antiretroviral therapy (ART) have 
drastically improved the quality of life for people with HIV infection, however owing to 
the persistence of latent HIV in the presence of therapy, patients must remain on 
therapy indefinitely [11].  
 
Despite these unquestioned successes, the problem is far from being resolved: even in 
countries with full access to antiretroviral treatment, life expectancy of people under 
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ARV therapy remains lower with respect to that of uninfected people [12]. Furthermore, 
large populations of HIV infected individuals are not diagnosed, remain untreated or not 
entered to the treatment at a very late stage of the diseases, represents an infected 
reservoir that increases risk of HIV transmission.  Moreover, the emergence of new 
comorbidities that may be partly associated with antiretroviral treatment (ARTs)  and partly 
with HIV itself represent a new problem in medical practice [10].  
 
 
1.1.3 HIV/AIDS in post HAART era 
A milestone in the history of HIV disease has been the availability of new classes of 
drugs in 1995-96, allowing the introduction of combination ARTs i.e. Highly Active 
Anti-Retroviral Therapy (HAART) and the gradual evolution of HIV infection into a 
chronic, usually non-fatal condition [13].  Ever since HIV has been recognized; 
reduction in viral load with increase in CD4 cell counts remained as the prime 
objectives of antiretroviral treatment along with the enchantment in health related 
quality of life and reduction in the impact of HIV transmission in the community. No 
matter how we define, the principal goal of HIV treatment is to prevent or reverse the 
progression of clinical illness [14]. 
 
There is no doubt that the unprecedented increase in the access to HIV treatment even 
in resource-limited settings has definitely contributed towards the global improvement 
in epidemics and HIV/AIDS related morbidity and mortality. This made possible due to 
virological suppression that occurs in approximately 70% of patients during the first 
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regimen of HAART [15], thus making infected individuals’ immunologic reconstitution 
possible [16,17]. Many factors contribute to immunological enhancements and 
virological suppression in making HAART as an effective tool [18] against HIV and 
AIDS and it was found that patients who present with advanced HIV infection and high 
levels of viral replication continue to be a challenge in the highly active antiretroviral 
treatment (HAART) era [19,20]. This become an important point of concern as 
substantial number of patients start their first-line antiretroviral therapy at an advanced 
stage of the disease [21].  
 
It is widely accepted that for HIV-positive persons on HAART, high levels of 
adherence to treatment regimens are essential for promoting viral suppression and 
preventing drug resistance [22], also since complete cure for HIV infection is not yet 
possible, treated people have to maintain lifelong adherence and facing the risk of 
delayed drug toxic effects [10]. In reality HAART poses many challenges to patients’ 
life affecting the outcome of these successes. Though many factors can contribute to 
such challenges including drug toxicities [23], it has been suggested that a lower pre-
HAART, CD4 count nadir may lead to a greater risk of experiencing drug related 
toxicities. In addition the frequency of a paradoxical immunologic response to HAART, 
defined as viral suppression without CD4 cell-count improvement, has also been 
reported in the literature as 8 to 42%, and around 15% in most occasions [20,24]. 
Therefore timely HIV diagnosis and induction of HAART remained a crucial step in 
determining the success of antiretroviral therapy. Looking into this the world health 
organization in its 2013 guidelines for antiretroviral therapy has recommended earlier 
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initiation of antiretroviral therapy (ART) at CD4 500  cells/μl or less for all adults and 
children above 5 years [25]. It further recommended initiation of ARTs irrespective of 
CD4 cell count or clinical stage for people co-infected with active tuberculosis disease 
or hepatitis B virus with severe liver disease, pregnant women, people in serodiscordant 
partnerships, and children under 5 years of age [25].  
 
 
1.2    Current status of HIV/AIDS 
 
1.2.1 Disease epidemics 
According to UNAIDS global AIDS epidemics report 2013; globally 35.3 million [32.2 
million–38.8 million] people were living with HIV indicating that about 75 million [63 
million–89 million] people have been infected with HIV since the beginning of 
epidemics [9]. During the recent years there has been an extraordinary increase in 
access to HIV treatment, care and facilities even in resource-limited settings where 
antiretroviral medications were previously unavailable, which has definitely contributed 
towards a global improvement in epidemics and HIV/AIDS related morbidity and 
mortality. As a matter of fact a 33% decline of new HIV infection was reported 
compare to the year 2001, however this positive news is not limited to the newly 
diagnosed infection as in 2012, also almost 1.6 million [1.4 million–1.9 million] people 
died from AIDS-related causes worldwide compared to 2.3 million [2.1 million–2.6 
million] in 2005 [9]. Sub-Saharan Africa with South and South-East Asia remained as 
top two regions accountable for most people living with HIV and HIV related deaths 
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[9]. Therefore though it is true that the number of globally newly infected people is 
declining, the burden of the epidemic continues to vary considerably between countries 
and regions [26]. 
 
 
1.2.2 Developed versus developing world 
It is indeed a great success as extraordinary escalation in access to HIV treatment even 
in resource-limited settings has been witnessed in recent years, and according to World 
Health Organization (WHO) data, access to antiretroviral drugs in low-middle income 
countries had rose 10 fold [9]. However in high-income countries, antiretroviral drugs 
have long been widely available and access to treatment has had a prominent impact on 
HIV-related mortality and introduction of  HAART had resulted in decline of as much 
as 85% in the mortality rate in HIV infected patients [27].  As the antiquity of 
HIV/AIDS has taken long time before in 1983 a retrovirus was (later named as human 
immune-deficiency virus) found responsible for causing this disease in human being 
[28], it was developing countries, particularly in sub-Saharan Africa, continued to bear 
the full brunt of an unchecked AIDS pandemic [2]. In the initial twenty five year history 
of this disease ninety-five percent (95%) of infections and deaths occurred in 
developing countries due to various factors [28], owing to the fact that dealing with the 
scientific, clinical, political, economic, and social problems posed by HIV/AIDS will 
continue to be a major struggle beyond the capacities of developing countries.  
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It was until the year 2000 when The International AIDS Conference in Durban, South 
Africa, proved a turning point which put the AIDS crisis in the developing world back 
on the front page of newspapers around the world, growing sentience among the general 
population and government leaders and raising a cry heard around the world [2]. This 
demanded a unique and truly global response to meld the resources, political power, and 
technical capacity of wealthy countries with the needs and capacities of developing 
countries [28]. As presented in the yearly global epidemic reports by UNAIDS, the 
developing world especially Sub-Saharan Africa, South Asia and South-East Asia still 
facing greater challenges in managing the epidemics of HIV/AIDS while the developed 
world has already witnessed a declining or steady levels to growing HIV epidemics 
[9,26]. Therefore the focus in dealing AIDS epidemic varied between developed and 
developing world, where developed world activities involve managing the predictable 
effects of any potent therapy, toxic effects and drug resistance rather than scrambling to 
provide basic care as in the case of developing nations [29]. 
 
 
1.2.3 Global challenges and strategies in controlling HIV/AIDS epidemics 
The human immunodeficiency virus and its incurable acquired immunodeficiency 
syndrome pose greater challenges despite the commendable achievements in recent 
years. As it is clearly evident and expected that the global prevalence of this disease 
would definitely going to increase in the coming years [9,30], there is a strong need for 
planning better strategies towards prevention and treatment of this disease. The first two 
decades of HIV/AIDS were marked with exploring disease and its treatment while the 
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epidemics were continuously growing at an alarming rate resulted in worse situations in 
Asian and African countries [31], now it is the time to deal with the issues still 
challenging the world especially developing countries for which better HIV surveillance 
programs are inevitable. There is an ever greater need to apply the concept of 
“Treatment for prevention”, requiring multiple preventive measures to curb the disease 
epidemics [32]. 
 
Though “zero new infection, zero discrimination and zero AIDS related deaths” 
remained as visionary global agenda of UNAIDS much work has to be done in context 
to growing HIV/AIDS related challenges and epidemics in various parts of the world. In 
order to continue this journey UNAIDS has set certain targets to be achieved by the 
year 2015, including reduction in HIV transmission, AIDS related mortalities and 
morbidities as well as reduction in stigma and discriminations towards HIV patients 
[26]. 
 
 
1.3 HIV/AIDS in Malaysia 
 
1.3.1 Historical background 
History of HIV/AIDS in Malaysia started when first cases were reported in 1986 [33–
35], since then country has seen considerable challenges in managing this disease [34]. 
Although initially IDUs were the main driving force of HIV epidemics in this country 
[34,36], at present it is still concentrated within most-at-risk populations (MARPS) 
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especially among IDU, sex workers and transgender population [33]. With the universal 
advancements in managing HIV/AIDS the country has witnessed significant reduction 
in new HIV cases by more than half from 28.4 per 100,000 populations in 2002 to 11.42 
cases per 100,000 populations in 2013 [9,34]. In the year 2013, there were 3,393 new 
cases were reported at an average of 9 cases per day though it is significant but lesser 
since the epidemic reached its peak in 2002 (6,978 cases) [34]. 
 
1.3.2 Current Status 
By the end of the year 2013, about 86324 patients were living with status of HIV and 
the country had reported a cumulative 101,672 HIV cases, 20,235 AIDS cases and 
16,340 deaths related to HIV/AIDS, thus giving reported PLWHA of 85,332 cases. 
Although male patients are mainly accounted for HIV epidemics in this country but the 
proportion of women reported with HIV has also increased dramatically in the last 
decade [34,36]. As the epidemic spread the pattern progressively shifted towards 
increasing infection rates in female with male/female ratio from 9.6 in 2000 to 4.5 in 
2010 to 3.7 in 2013.  As explain earlier another important aspect is the shift of infection 
epidemics from IDUs to sexual transfer which is evident by increasingly more sexual 
transmission with IDU/sexual transmission ratio now declined from 3.9 in 2000 to 0.3 
in 2013 with about 34.3% reported cases were among young individuals aged between 
13 to 29 years [34]. The Malaysian Ministry of Health has a separate HIV/STI (sexually 
transmitted infection) sector working as national AIDS program (NAP) and county’s 
improved control of HIV epidemics is due to a multi-sector AIDS response involving 
various departments and ministries [34]. In addition to government efforts, Malaysian 
 10   
 
AIDS Council (MAC) also works with many partner organizations with a vision of 
building “society free from the negative impact of HIV and AIDS where the AIDS 
epidemic is under control through comprehensive prevention, treatment, care, support 
and impact alleviation services particularly for the most vulnerable and marginalized 
populations” [37]. 
 
1.3.3 Challenges in HIV/AIDS care 
While significant progress has been made in the country’s response to HIV/AIDS, 
scaling up prevention, treatment and care to meet universal access goals remain a 
challenge in this country. The Ministry of Health, Malaysia in its 2014 global AIDS 
response report [34] has highlighted key challenges in HIV management including; 
 
a) Increase knowledge and awareness among younger population towards risky 
behavior. 
b) Scaling up HIV testing for better management 
c) To curb sexual transmission of HIV 
d) Coverage and integration of various service sectors including primary health. 
e) To improvise TB/HIV care 
f) Elimination of mother to child transmission (MTCT) 
g) Public –private partnership for better HIV control 
h) To eliminate stigma and discrimination towards HIV/AIDS 
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Many factors including gender inequity, silence, denial [38] and ignorance fuel the 
epidemics in Malaysia. In addition urban and rural children and adolescents' 
vulnerability to HIV further increases, therefore children with HIV/AIDS have been 
reported to have faced stigma and exposed to and experience acts of discrimination 
leading to many challenges [36]. 
 
1.4 HIV/AIDS and Quality of life  
 
1.4.1 Quality of life (QoL) & Health related quality of life (HRQoL) 
WHO defines quality of life as an individual's perception of their position in life in the 
context of the culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns [39]. While quality of life (QoL) is a broad 
concept that incorporates individual’s perceptions of factors affecting his or her general 
well-being, health related quality of life (HRQoL) focuses specifically on quality of life 
related to health. WHO defines the concept of HRQoL as, “a state of complete physical, 
mental and social well-being and not merely the absence of disease of infirmity.” In 
recent years, interest in measuring HRQoL increased with the publication of more 
HRQoL studies. QoL is in fact, a concept that incorporated all factors affecting a person 
(economic status, social functioning, self-satisfaction and well-being) while HRQoL 
focuses more on QoL related to health. Major aspects of HRQoL include physical, 
social, emotional and cognitive functioning; mobility and self-care; patient perception 
of health; and symptoms[40]. Patrick and Erickson broadly defined HRQoL as the 
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“value assigned to the duration of life as modified by the impairments, functional states, 
perceptions, and social opportunities that are influenced by disease, injury, treatment, or 
policy [41] 
 
1.4.2 Importance of HRQoL among HIV/AIDS patients 
As discussed earlier despite the global decline in number of people newly infected with 
HIV/AIDS, many nations are still fronting challenges with expending epidemics, hence 
despite much of the news on HIV/AIDS is encouraging in present era, challenges sill 
remain [26]. Numerous factors contribute to this high prevalence; from low levels 
testing and linkage to care and prevention, to poor retention in care and adherence to 
antiretroviral treatment [42]. Though much has been achieved in terms of treatment 
outcomes due to the global solidarity in the AIDS response during the past decade [26], 
the chronicity of HIVA/IDS still poses challenges to patients’ life [43]. Therefore until 
the day HIV/AIDS cure will be possible, delay in HIV/AIDS related mortality and 
related complications with improve quality of life (QoL) will remain as main outcomes 
of the treatment and in order to achieve this, equal and active participation of patient in 
the whole process of treatment is imperative. This accentuates on assessment of patient 
perspective and understanding toward disease and its management [44].  
 
Health-related quality of life is increasingly recognized as an important outcome and as 
a complement to traditional biological end points such as mortality. Unless a cure is 
found the majority of PLWHA will continue to suffer from this disease and its treatment 
with serious impact on quality of life [45–47]. Therefore, development, assessment and 
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implementation of a reliable and valid cross cultural quality of life measure is necessary 
that can be used not only to assess the physical and medical needs of PLWHA, but also 
their psychological, social, environmental, and spiritual determinants in wider context 
of better disease management.   
 
HRQoL has emerged as an important issue in the management of HIV infection. HIV 
infected patients generally demonstrate a HRQoL that is lower than that of the general 
population, similarly those with AIDS reported lower HRQoL than patients with other 
chronic conditions like cancer or depression. Assessment on HRQoL has been found to 
be effective in enhancing communication between patients and health care providers 
[27], where it has allowed patients to review those areas of HRQoL that most concern to 
them. This could also be used to track changes in functional status over time, especially 
in monitoring treatment effects [48]. Therefore monitoring HRQoL can also help to 
determine whether adverse effects outweigh value of desired clinical response. [40,49]. 
 
1.5 Adverse drug reactions (ADRs) and HIV/AIDS 
 
 
1.5.1 Adverse drug reactions and HRQoL 
 
Detection, monitoring and managing ADRs are essentially integral part in any field of 
medicine and HIV/AIDS is not different from that [50]. It is well established that 
HAART employs range of acute and chronic adverse drug events affecting patients’ 
adherence and resulting in issues related to patient overall compliance [51,52]. Similar 
to other chronic illnesses, HIV/AIDS patients’ experienced ADRs affect HRQoL, a 
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prime therapeutic objective of HIV/AIDS treatment. Studies have reported that these 
medications are associated with significant safety concerns including serious ADRs, 
with both short- and long-term effects, affecting many organ systems, which may 
damage confidence in any national ARV program and affect patient adherence [53,54].  
It is logical and expected that most of the time these patients are provided with expert 
care on the co-morbidities in addition to disease itself, however a routine assessment 
and evaluation of ADRs can help in devising more effective treatment programs which 
in turn can help in addressing issues like adherence and poor quality of life among 
HIV/AIDS patients, since long-term complications of this disease are multifactorial and 
can be related to the virus itself or to adverse effects of antiretroviral therapy [55]. 
Adherence to treatment is closely linked to the occurrence of ADRs and it would be 
pointless simply changing the medications without addressing the adherence barriers. It 
is thus imperative that clinicians clearly understand ADRs, readily recognize them in 
their patients and manage them effectively [56,57]. 
 
HIV-infected persons normally complained of adverse effects due to antiretroviral 
therapy ranges from fatigue, pain, nausea and vomiting, skin rashes, sleep disturbances, 
sexual dysfunction, and body image issues and many more [48,55,58–62]. All these 
adverse effects definitely interferes with their normal daily activities and hence exerting 
impact on patients’ overall quality of life [38,46,63,64].   
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1.5.2 Importance of measuring ADRs and HRQoL 
 
Living with HIV/AIDS, affects not only the physical health but also the mental and 
social well-being of infected individuals.  HIV can no longer be defined as simply a 
virus but a social and historical event on how patients survive along with HIV. Issues 
that include personal safety, human rights and other aspects of political and social 
infrastructure can radically affect patients’ quality of life [40]. The assessment of 
HRQoL as an outcome of management has increased since its introduction in late 
1940s. It has the potential to facilitate patient’s care by constructing better management 
and care plan for the patients. Monitoring and optimizing HRQoL may improve 
adherence to therapy, therefore HRQoL measures serve as an important gadget in 
evaluating patients’ well-being and health improvement. The purpose of assessing 
HRQoL is mainly to discuss on issues that are particularly relevant to patients with 
HIV/AIDS, and also to provide an overview of common research based HRQoL 
assessment tools used in patients population [49]. Therefore, routine clinical assessment 
of health related quality of life in persons with HIV infection is vital. It has the potential 
to improve care by assessing and monitoring treatment effects, enhancing 
communication between patients, and also tracking back their functional status over 
time [40,49]. 
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1.6  Patients’ perspective on Disease, Treatment and Care 
 
1.6.1 Importance of exploring Patients’ Perspective 
Lack of information and understandings about disease and drugs in usage have been 
highlighted among most significant reasons why HIV/AIDS individuals do not 
adequately follow their treatment [32,63,65]. Beliefs about health and illness, in 
particular about the necessity of medication to ward off illness and concerns about 
potential medicine‐related adverse events have been found to be influential in both HIV 
and other disease areas. The emic perspectives are useful for examining when we are 
seeing things from our own point of view and when we are trying to understand 
someone else’s view of things, which shows the meaning that people attached to things 
from their own cultural perspective [66].  
 
 
1.6.2 HIV/AIDS and Patients understandings 
Patients with chronic diseases might be expected to encounter increasingly complex 
barriers given the need for long-term care and treatment and it is clear that these barriers 
can have very serious consequences in terms of delayed treatment, inappropriate 
healthcare-seeking behaviors, poor adherence to the treatment regimens or even a 
decision to forego treatment [67]. HIV/AIDS is widely recognized as a chronic illness 
within HIV care, but is often excluded from chronic disease lists outside the field. 
Patient related principle elements of chronic disease management such as understanding 
illness & wellness, health promoting behaviors, preventing transmission are some of the 
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essential elements in the integrated framework of chronic HIV care [68]. Therefore 
exploring such elements can help improvising existing HIV/AIDS treatment program by 
incorporating patients’ perspectives into it since such perceptions influences their 
health-seeking behavior and can complicate their treatment outcomes [67]. This in turn 
can help in optimizing patient care as well as dealing issues of non-compliance, delay in 
treatment, screening refusal etc.  
 
 
1.6.3 Use of Qualitative methods in HIV/AIDS  
The use of qualitative methods is becoming more common in medical research in 
general and HIV/AIDS in particular [69–71].  Undeniably, some researches have 
suggested that qualitative research is fundamental to our understanding of the socio-
behavioral aspects of HIV disease [72]. Studies in various parts of the world have 
revealed poor patient understandings and beliefs towards HIV/AIDS, in addition to 
numerous barriers to HIV screening; however only limited data is available as many of 
them focuses particular aspects in HIV care. Various aspects of HIV care related to 
PLWHA understandings and point of view including disease transmission and screening 
[73], refusal to screening [74], spirituality in relation to HIV/AIDS care [75], status 
disclosure [76] and adherence [77] etc. have been explored by using qualitative methods 
and generated useful data that helped in better understanding of the issues involved. In 
addition patients’ needs, satisfaction and quality of life have also been learnt through 
qualitative findings [78].  
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1.6.4 Qualitative studies on HIV/AIDS in Malaysia 
As reported earlier, Malaysia has seen a decline in annually reported new cases of 
HIV/AIDS [33],  however despite this achievement the disease postures many 
challenges to the society and individual patients [34]. Malaysia is a country with 
extensive cultural and ethnic diversities with range of spiritual traditions and believes 
[34,79]. Also in the presence of complementary medication and treatment systems, 
evaluating patients’ perspective towards HIV/AIDS and related issues is undeniably 
important and will definitely help in better understanding of real life issues faced by 
PLWHA. Another strong reason for need of such explorations is the fact that studies 
have found deficits in the spectrum of engagement in HIV care including late diagnosis, 
suboptimal linkage to and retention in HIV care, insufficient use of antiretroviral 
therapy, and suboptimal adherence to therapy, posturing significant barriers to 
achieving optimal treatment outcomes [18].  
 
 
 
 
 
 
 
 
 
 
 19   
 
1.7 Summary 
Acknowledging the historical global impact of HIV/AIDS epidemics although 
significant achievements have been made in terms of controlling disease epidemics 
globally and access to care facilities, there are still considerable challenges exist in 
controlling disease epidemics in resource limited developing nations [26] as well as the 
social impact of this disease in many societies.  People infected with HIV/AIDS are still 
facing many defies due to stigma, discrimination and social injustice in various parts of 
the world [26]. In 2011 United Nations political declaration on HIV and AIDS therefore 
pledged to intensify global efforts in elimination HIV/AIDS and in order to achieve that 
specific targets were set to be achieved by the year 2015 including measures to curb 
HIV epidemics and its impact on patients’ life [26]. Though such ambitious targets and 
commitments is more of global political agenda, it has lesser meanings and importance 
for individual HIV/AIDS patients who continue to struggle with their fight against 
disease as well as the right to live without stigma, discrimination and other forms of 
social injustice in the societies.  
 
Considering HIV/AIDS as one of the greatest menace for mankind in the modern 
history of medicine the reasons for its sudden emergence, epidemic spread, and unique 
pathogenicity have been a subject of intense study since HIV was first discovered [4]. 
Therefore, unquestionably there is an ever greater need to intensify more contextualized 
findings from developing countries casing various aspects of disease and patients life as 
much of the data unfortunately still comes from developed part of the world [80]. In 
conclusion HIV/AIDS is now a disease driven by social inequalities and comprehensive 
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interventions that demonstrate how the adverse demographic and psychosocial factors 
affect PLWH are a fundamental part of a truly effective therapeutic strategy [46] 
 
The modern history of medicine has witnessed a devastated epidemic of HIV/AIDS 
during the past three decades that has not only resulted in millions of death around the 
globe but with greater impressions on societies. With the advent of HAART the face of 
this disease has been greatly modified and it has become a chronic disease [77,81], with 
increased life expectancy for affected patients [77]. However this treatment causes 
many challenges to patients’ life [82,83] which require understanding and rectification 
from care providers and planners. Though much have been achieved in terms of disease 
epidemic and its impact on both patient and societies in develop world [9], socio-
economic disparities between developed and developing world and various other forms 
of health disparities are undeniably a major cause of failure in controlling disease 
epidemics in developing world and which also poses challenges in achieving global 
HIV outcomes [26,30,84–86].   
 
 
Malaysia is a multiethnic and multi religious country with Muslims predominates 
[34,38], with in the wider perspective of this, the country has made significant progress 
in controlling HIV/AIDS epidemics however challenges remained. Dealing with an 
illness like HIV/AIDS which has its impact on both patient as well as society is not an 
easy thing to be achieved when require to dealt with people from various religious and 
cultural backgrounds. Through challenges are there, Malaysia has made great inroads in 
controlling its HIV/AIDS epidemic, considering issues surrounding HIV are 
exceedingly sensitive, engaging with religious leaders is certainly no small feat [79], 
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however there is a need to focus on areas in HIV care that remained unexplored or 
neglected, in order to withstand with global response to the disease. 
 
 
1.8 Problem Statement 
 
There is no doubt about the overall positive impact of HAART in managing HIV & 
AIDS, however the face change of HIV/AIDS as a chronic infection/disease presents 
challenges for patients and health-care professionals, and measures of QOL can provide 
important information in behavioral and clinical studies of ARTs [64]. In the era of new 
antiretroviral treatments that have dramatically reduced both morbidity and mortality, a 
primary goal is to maximize function and wellbeing in the everyday life of HIV-
infected patients. To be able to do so, it would be important for clinicians and policy 
makers to identify factors that influence health-related quality of life (HRQoL) [87].  
 
 
Due to the well-established antiretroviral toxicities experienced, poor adherence and 
compliance is often seen among HIV/AIDS patients [23], with decreased health related 
quality of life. Many factors including socio-demographics, comorbidities, traditional 
and complementary medication use could also increase the likely hood of ADR 
incidents [46,50,88] and hence monitoring ADRs and measuring quality of life should 
have been considered as integral part of any HIV program. The initial two decades of 
HIV/AIDS were more focused on drug discovery and optimizing treatment outcome 
and therefore the importance of drug safety monitoring was over- shadowed by the need 
to develop potent therapies capable of arresting a fatal disease process [50].   
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Qualitative researches in health care are gaining popularity in providing better 
understandings from both patients and health care professionals perspectives [89]. Due 
to the fact that qualitative researches provided more descriptive, contextually rich data it 
has enabled us to appreciate the elusiveness and complexity of HIV-related behaviors 
and the importance of lifestyle and culture in determining crucial factors affecting 
patients’ life and outcome of an HIV care program. In addition it has also proved 
invaluable in formative research and development, especially in mapping the profiles of 
difficult- to-access social networks of target populations [71]. Furthermore it can help in 
clarifying issues and phenomenon found in quantitative findings and help us fill in the 
gaps in our knowledge and understandings [71,90]. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 HIV/AIDS and adverse drug reactions 
There is no doubt that HAART significantly reduces morbidity and mortality among 
PLWHA, however, the HAART associated adverse drug reaction often adversely 
affecting the QoL of these patients. This in turn, reduces patients’ adherence to HAART 
regimen and raises other issues of compliance and patient retention to care. Although all 
antiretroviral drugs carry ADR profile, protease inhibitors are among the most common 
causing adverse drug reactions [48,55,91]. A study by Tramarin et al concluded that 
HIV/AIDS patients with PI induced diarrhea had significantly lower scores in all quality 
of life domains compared to those without diarrhea (p<0.05), therefore study 
recommended significant adverse effect of diarrhea on quality of life should be 
considered when choosing the appropriate antiretroviral drugs regimen [92]. 
Lipodystrophy a syndrome, is characterized by abnormal body fat redistribution and 
metabolic abnormalities, is often manifested with enlarged abdomen, thinning of 
extremities, buffalo hump and sunken facial cheeks, is regarded as an important adverse 
effect of HAART [29,48,50,53,55,81,91,93–95], which had been identified to 
significantly reduce QoL among HIV/AIDS patients [64,96–102]. In a study involving 
125 patients with lipodystrophy symptoms, there were more than 40% of patients 
experienced pain, physical limitation, poor health status and lower QoL [96], similarly a 
study by Nicholas et al concluded that quality of life is affected by HIV symptoms and 
that lipodystrophy-related symptoms may negatively affect quality of life [96].  
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Lipodystrophy has increase fear of HIV patients in taking ART and a recent published 
paper found that 85% of patients with lipodystrophy reported that changes have been 
noticed by family, friends and work colleagues. Disfigurement caused stigma, and 
attractiveness; it also influence social relations and lead to anxiety and depression 
[99,101]. Similar findings were reported in a Rwandan study shown that, females 
especially claimed that body fat redistribution negatively affected their physical and 
emotional health [103]. Qualitative studies have also found psychosocial implications of 
lipodystrophy on HIV individuals and have found it to be associated with problems with 
personal and family relationships and social isolations [98].  
 
HIV patients at the beginning of their antiretroviral treatment can frequently show a 
wide variety of adverse drug effects such as skin rashes, hyperpigmentation, hair loss, 
hypersensitivity reactions, injection site reaction, urticarial reaction, erythema 
multiforme, toxic epidermal necrosis or Stevens-Johnson syndrome, hence early 
identification and management of these including identification of the causative agent, 
are vital to prevent the progression of these reactions [58]. In addition to patients 
reported toxicities, long term toxicities of antiretroviral medications presents greater 
challenges and raising issues related to medication and treatment adherence [23].  
 
Concomitant use of traditional herbal remedies with HAART has also been found to 
adversely affect the effectiveness of treatment regimen and QoL among PLWHA. In 
study done in Zimbabwe, concomitant use of herbal remedies with antiretroviral drugs 
(ART) found significantly more incidences of skin rash (odds ratio = 2.5, p-value = 
